Our bioinformatic analysis confirmed significantly higher gene expression of the inflammasome component ASC along with the downstream effectors IL1B and IL18 in the bone marrow of AML patients compared to healthy control (HC) samples (Fig. 1A). This evidence concerns the gene IL1B and acute myeloid leukemia.